Sign up Australia
Proactive Investors - Run By Investors For Investors

MaxCyte chief says potential of breakthrough technology CARMA should not be underestimated

Newly-listed MaxCyte (LON:MXCT) is a drug discovery company that also licences and sells its cell technology. 
Chief executive Doug Doerfler talks to Proactive’s Charlotte Kan about the company’s hybrid model, which means it is one of the few biotechs actually generating substantial revenues. “It is an unusual, but good position to be,” he says.
Doerfler also gives us an insight into its potential blockbuster, CARMA, which is being developed to re-programme the body’s immune system to kill cancer.
“I can’t overestimate how important this for medicine and also for the company,” Doerfler adds.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd and Pacific American Coal Ltd at our event, Sydney , 19 November 2018. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Article
October 10 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use